corner
Healthy Skepticism
Join us to help reduce harm from misleading health information.
Increase font size   Decrease font size   Print-friendly view   Print
Register Log in

Healthy Skepticism Library item: 16176

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

 

Publication type: news

Moves to ban compensation deals in the US
PM Live 2009 Aug 3
http://www.pmlive.com/find_an_article/allarticles/categories/General/2009/august/news/moves_to_ban_compensation_deals_in_the_us


Full text:

The House Energy and Commerce Committee in the US has voted to ban ethical pharma companies paying generics manufacturers to delay the launch of cheaper generic versions of their branded drugs.

The committee approved, by a voice vote, a bill to stop branded pharma companies from offering generics firms compensation to delay entry to market. The Senate is also considering a similar bill. It is likely that the proposed bill will get presidential backing: President Barak Obama co-sponsored an earlier version of the legislation while a member of the Senate.

According to the Federal Trade Commission (FTC) compensation deals between pharma and generics firms cost Americans $3.5bn each year.

In Europe, Competition Commissioner, Neelie Kroes, has promised to oppose compensation deals, which she said increased European consumers’ healthcare bills by 20 per cent between 2000 and 2007.

There needs to be more competition and less red tape in the pharmaceutical industry, Kroes said last month. The proclamation came as the European Commission published its final report on competition in the sector and stepped up its scrutiny of business practices under EC antitrust laws.

“The sector is too important to the health and finances of Europe’s citizens and governments to accept anything less than best. The enquiry has told us what is wrong with the sector, and now it is time to act. When it comes to generic entry, every week and month of delay costs money to patients and taxpayers,” said Kroes. “We will not hesitate to apply the antitrust rules where such delays result from anticompetitive practices,” she added.

 

  Healthy Skepticism on RSS   Healthy Skepticism on Facebook   Healthy Skepticism on Twitter

Please
Click to Register

(read more)

then
Click to Log in
for free access to more features of this website.

Forgot your username or password?

You are invited to
apply for membership
of Healthy Skepticism,
if you support our aims.

Pay a subscription

Support our work with a donation

Buy Healthy Skepticism T Shirts


If there is something you don't like, please tell us. If you like our work, please tell others.

Email a Friend








What these howls of outrage and hurt amount to is that the medical profession is distressed to find its high opinion of itself not shared by writers of [prescription] drug advertising. It would be a great step forward if doctors stopped bemoaning this attack on their professional maturity and began recognizing how thoroughly justified it is.
- Pierre R. Garai (advertising executive) 1963